Evidence for Chronically Altered Serotonin Function in the Cerebral Cortex of Female 3,4-methylenedioxymethamphetamine Polydrug Users

Overview

Journal Arch Gen Psychiatry

Specialty Psychiatry

Date 2011 Dec 8

PMID 22147810

Citations 12

Authors

Christina R Di Iorio

Tristan J Watkins

Mary S Dietrich

Aize Cao

Jennifer U Blackford

Baxter Rogers

Mohammed S Ansari

Ronald M Baldwin

Rui Li

Robert M Kessler

Ronald M Salomon

Margaret Benningfield

Ronald L Cowan

Affiliations

Soon will be listed here.

Abstract

Context: MDMA (3,4-methylenedioxymethamphetamine, also popularly known as "ecstasy") is a popular recreational drug that produces loss of serotonin axons in animal models. Whether MDMA produces chronic reductions in serotonin signaling in humans remains controversial.

Objective: To determine whether MDMA use is associated with chronic reductions in serotonin signaling in the cerebral cortex of women as reflected by increased serotonin(2A) receptor levels.

Design: Cross-sectional case-control study comparing serotonin(2A) receptor levels in abstinent female MDMA polydrug users with those in women who did not use MDMA (within-group design assessing the association of lifetime MDMA use and serotonin(2A) receptors). Case participants were abstinent from MDMA use for at least 90 days as verified by analysis of hair samples. The serotonin(2A) receptor levels in the cerebral cortex were determined using serotonin(2A)-specific positron emission tomography with radioligand fluorine 18-labeled setoperone as the tracer.

Setting: Academic medical center research laboratory.

Participants: A total of 14 female MDMA users and 10 women who did not use MDMA (controls). The main exclusion criteria were nondrug-related DSM-IV Axis I psychiatric disorders and general medical illness.

Main Outcome Measures: Cortical serotonin(2A) receptor nondisplaceable binding potential (serotonin(2A)BP(ND)).

Results: MDMA users had increased serotonin(2A)BP(ND) in occipital-parietal (19.7%), temporal (20.5%), occipitotemporal-parietal (18.3%), frontal (16.6%), and frontoparietal (18.5%) regions (corrected P < .05). Lifetime MDMA use was positively associated with serotonin(2A)BP(ND) in frontoparietal (β = 0.665; P = .007), occipitotemporal (β = 0.798; P = .002), frontolimbic (β = 0.634; P = .02), and frontal (β = 0.691; P = .008) regions. In contrast, there were no regions in which MDMA use was inversely associated with receptor levels. There were no statistically significant effects of the duration of MDMA abstinence on serotonin(2A)BP(ND).

Conclusions: The recreational use of MDMA is associated with long-lasting increases in serotonin(2A) receptor density. Serotonin(2A) receptor levels correlate positively with lifetime MDMA use and do not decrease with abstinence. These results suggest that MDMA use produces chronic serotonin neurotoxicity in humans. Given the broad role of serotonin in human brain function, the possibility for therapeutic MDMA use, and the widespread recreational popularity of this drug, these results have critical public health implications.

Citing Articles

Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy.

Oeri H J Psychopharmacol. 2020; 35(5):512-536.

PMID: 32909493 PMC: 8155739. DOI: 10.1177/0269881120920420.

Locomotor effects of 3,4-methylenedioxymethamphetamine (MDMA) and its deuterated form in mice: psychostimulant effects, stereotypy, and sensitization.

Berquist M, Leth-Petersen S, Kristensen J, Fantegrossi W Psychopharmacology (Berl). 2019; 237(2):431-442.

PMID: 31729537 PMC: 7388080. DOI: 10.1007/s00213-019-05380-3.

Neuronal and peripheral damages induced by synthetic psychoactive substances: an update of recent findings from human and animal studies.

Costa G, De Luca M, Piras G, Marongiu J, Fattore L, Simola N Neural Regen Res. 2019; 15(5):802-816.

PMID: 31719240 PMC: 6990793. DOI: 10.4103/1673-5374.268895.

The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies.

Vegting Y, Reneman L, Booij J Psychopharmacology (Berl). 2016; 233(19-20):3473-501.

PMID: 27568200 PMC: 5021729. DOI: 10.1007/s00213-016-4396-5.

Central 5-HT neurotransmission modulates weight loss following gastric bypass surgery in obese individuals.

Haahr M, Hansen D, Fisher P, Svarer C, Stenbaek D, Madsen K J Neurosci. 2015; 35(14):5884-9.

PMID: 25855196 PMC: 6605315. DOI: 10.1523/JNEUROSCI.3348-14.2015.

References

Morgan M . Recreational use of "ecstasy" (MDMA) is associated with elevated impulsivity. Neuropsychopharmacology. 1998; 19(4):252-64. DOI: 10.1016/S0893-133X(98)00012-8. View

Soria-Fregozo C, Perez-Vega M, Gonzalez-Burgos I, Feria-Velasco A, Beas-Zarate C . Prefrontal serotonergic denervation induces increase in the density of 5-HT2A receptors in adult rat prefrontal cortex. Neurochem Res. 2008; 33(11):2350-7. DOI: 10.1007/s11064-008-9740-7. View

Cowan R, Haga E, Frederick B, Dietrich M, Vimal R, Lukas S . MDMA use is associated with increased spatial BOLD fMRI visual cortex activation in human MDMA users. Pharmacol Biochem Behav. 2006; 84(2):219-28. DOI: 10.1016/j.pbb.2006.04.024. View

Reneman L, Booij J, Schmand B, van den Brink W, Gunning B . Memory disturbances in "Ecstasy" users are correlated with an altered brain serotonin neurotransmission. Psychopharmacology (Berl). 2001; 148(3):322-4. DOI: 10.1007/s002130050057. View

Liechti M, Gamma A, Vollenweider F . Gender differences in the subjective effects of MDMA. Psychopharmacology (Berl). 2001; 154(2):161-8. DOI: 10.1007/s002130000648. View

Compan V, Segu L, Buhot M, Daszuta A . Differential effects of serotonin (5-HT) lesions and synthesis blockade on neuropeptide-Y immunoreactivity and 5-HT1A, 5-HT1B/1D and 5-HT2A/2C receptor binding sites in the rat cerebral cortex. Brain Res. 1998; 795(1-2):264-76. DOI: 10.1016/s0006-8993(98)00316-3. View

Hatzidimitriou G, McCann U, Ricaurte G . Altered serotonin innervation patterns in the forebrain of monkeys treated with (+/-)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci. 1999; 19(12):5096-107. PMC: 6782677. View

Trichard C, Paillere-Martinot M, Blin J, Feline A, Martinot J . No serotonin 5-HT2A receptor density abnormality in the cortex of schizophrenic patients studied with PET. Schizophr Res. 1998; 31(1):13-7. DOI: 10.1016/s0920-9964(98)00014-0. View

Maes F, Collignon A, Vandermeulen D, Marchal G, Suetens P . Multimodality image registration by maximization of mutual information. IEEE Trans Med Imaging. 1997; 16(2):187-98. DOI: 10.1109/42.563664. View

10.

Wilson M, Ricaurte G, Molliver M . Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine. Neuroscience. 1989; 28(1):121-37. DOI: 10.1016/0306-4522(89)90237-6. View

11.

Beck A, Ward C, Mendelson M, Mock J, ERBAUGH J . An inventory for measuring depression. Arch Gen Psychiatry. 1961; 4:561-71. DOI: 10.1001/archpsyc.1961.01710120031004. View

12.

Sheehan D, Lecrubier Y, Sheehan K, Amorim P, Janavs J, Weiller E . The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1999; 59 Suppl 20:22-33;quiz 34-57. View

13.

de Win M, Reneman L, Reitsma J, den Heeten G, Booij J, van den Brink W . Mood disorders and serotonin transporter density in ecstasy users--the influence of long-term abstention, dose, and gender. Psychopharmacology (Berl). 2004; 173(3-4):376-82. DOI: 10.1007/s00213-003-1723-4. View

14.

Yubero-Lahoz S, Pardo R, Farre M, OMahony B, Torrens M, Mustata C . Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans. Clin Pharmacokinet. 2011; 50(5):319-29. DOI: 10.2165/11584550-000000000-00000. View

15.

Verhoeff N, Meyer J, Kecojevic A, Hussey D, Lewis R, Tauscher J . A voxel-by-voxel analysis of [18F]setoperone PET data shows no substantial serotonin 5-HT(2A) receptor changes in schizophrenia. Psychiatry Res. 2000; 99(3):123-35. DOI: 10.1016/s0165-1781(00)00198-0. View

16.

Kalechstein A, De La Garza 2nd R, Mahoney 3rd J, Fantegrossi W, Newton T . MDMA use and neurocognition: a meta-analytic review. Psychopharmacology (Berl). 2006; 189(4):531-7. DOI: 10.1007/s00213-006-0601-2. View

17.

Capela J, Carmo H, Remiao F, Bastos M, Meisel A, Carvalho F . Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol Neurobiol. 2009; 39(3):210-71. DOI: 10.1007/s12035-009-8064-1. View

18.

McCann U, Edwards R, Smith M, Kelley K, Wilson M, Sgambati F . Altered pain responses in abstinent (±)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users. Psychopharmacology (Berl). 2011; 217(4):475-84. DOI: 10.1007/s00213-011-2303-7. View

19.

Biver F, Lotstra F, Monclus M, Wikler D, Damhaut P, Mendlewicz J . Sex difference in 5HT2 receptor in the living human brain. Neurosci Lett. 1996; 204(1-2):25-8. DOI: 10.1016/0304-3940(96)12307-7. View

20.

Beck A, Steer R . Internal consistencies of the original and revised Beck Depression Inventory. J Clin Psychol. 1984; 40(6):1365-7. DOI: 10.1002/1097-4679(198411)40:6<1365::aid-jclp2270400615>3.0.co;2-d. View